Berg Pharma, LLC

Industry observers had long been waiting for Gilead Sciences Inc. to make a major acquisition, and its $11.9bn purchase of Kite Pharma Inc. fit that bill and helps super-charge its cancer pipe

Company Changes ALBRIGHT , Charles, PhD To: Editas Medicine Inc. , CSO (August) From: Bristol-Myers Squibb Co., VP, Genetically Defined Diseases & Genomics Phone: 617-401-9000 BAERTSCHI , Gabr

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in